NCNA · NuCana plc
Market Cap
$4.19M
Shares
4.16M
Volume · Oct 21
30.15K
Avg daily vol (3M)
118.68K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.96
Open$1.00
Day$0.96–1.01
52W close$0.96–4.43
Avg vol 30d180K
Short int100K · 2.4% float · 1.0d
Short vol11%
DataJan 2020–Oct 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2,930,097.9%
Year over year · more shares
Price change (1Y)
-79.8%
Trailing year
Short interest
2.4%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−48%
below
Price vs 50-day avg
−26%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−27%
trailing
6-month return
−55%
trailing
YTD return
−73%
this year
Relative strength
−62%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.40% of float · ▼ -6.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 3-yr range
Squeeze score
45
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
9.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−48%
Bearish
Price vs 50-day avg
−26%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+25% holders QoQ · +4 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.40% of float · ▼ -6.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $4
vs 200-day avg -48%
vs 50-day avg -26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NCNA
this stock
NuCana plc
|
$4.19M | -73.3% | — | — | 2.4% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$131.39B | +15.7% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +733.5% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.4% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.22B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NCNA | -8.4% | -26.6% | -54.8% | -28.7% | -73.3% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -8.8% | -27.3% | -62.4% | -30.1% | -86.7% |